Nuveen Asset Management LLC Buys 184,712 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Nuveen Asset Management LLC boosted its position in RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Rating) by 168.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 294,088 shares of the company’s stock after buying an additional 184,712 shares during the period. Nuveen Asset Management LLC owned approximately 0.99% of RAPT Therapeutics worth $7,076,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. MetLife Investment Management LLC increased its position in shares of RAPT Therapeutics by 6.9% during the third quarter. MetLife Investment Management LLC now owns 13,805 shares of the company’s stock valued at $332,000 after acquiring an additional 886 shares in the last quarter. Credit Suisse AG lifted its stake in shares of RAPT Therapeutics by 34.5% in the third quarter. Credit Suisse AG now owns 19,299 shares of the company’s stock worth $463,000 after buying an additional 4,951 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of RAPT Therapeutics in the third quarter valued at approximately $226,000. ExodusPoint Capital Management LP lifted its position in shares of RAPT Therapeutics by 78.2% during the 3rd quarter. ExodusPoint Capital Management LP now owns 93,775 shares of the company’s stock worth $2,256,000 after buying an additional 41,153 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of RAPT Therapeutics by 5.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 298,975 shares of the company’s stock worth $7,194,000 after purchasing an additional 14,677 shares during the period.

RAPT Therapeutics Price Performance

Shares of NASDAQ RAPT opened at $24.70 on Monday. RAPT Therapeutics, Inc. has a 1 year low of $9.85 and a 1 year high of $32.45. The stock has a market cap of $738.78 million, a PE ratio of -9.69 and a beta of 0.46. The firm has a fifty day moving average price of $27.15 and a 200-day moving average price of $23.51.

Insider Buying and Selling

In other RAPT Therapeutics news, insider William Ho sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 24th. The shares were sold at an average price of $30.00, for a total transaction of $150,000.00. Following the completion of the transaction, the insider now owns 30,072 shares in the company, valued at approximately $902,160. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold a total of 15,742 shares of company stock worth $384,252 in the last 90 days. Insiders own 5.00% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Guggenheim initiated coverage on RAPT Therapeutics in a research note on Wednesday, January 4th. They set a “buy” rating and a $55.00 price objective on the stock. Piper Sandler dropped their price target on RAPT Therapeutics from $34.00 to $33.00 in a research note on Thursday, December 8th. Wells Fargo & Company cut their target price on RAPT Therapeutics from $55.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, January 4th. The Goldman Sachs Group assumed coverage on RAPT Therapeutics in a research report on Thursday, December 1st. They set a “buy” rating and a $27.00 price target for the company. Finally, HC Wainwright dropped their price target on RAPT Therapeutics from $53.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, November 14th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, RAPT Therapeutics presently has a consensus rating of “Buy” and an average price target of $44.14.

RAPT Therapeutics Company Profile

(Get Rating)

Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.